Recent Advances in the Treatment of Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

EP. 1: BTK Inhibitors as Frontline Therapy for CLL

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

January 24th 2022

The rationale for using Bruton tyrosine kinase inhibitors, such as the first-generation option, ibrutinib, as first-line treatment for chronic lymphocytic leukemia.

EP. 2: Ibrutinib Therapy for CLL: Long-Term Data

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Nicole Lamanna, MD

January 24th 2022

Reactions to longer-term follow-up data presented in 2021 on the use of ibrutinib as frontline treatment for patients with chronic lymphocytic leukemia.

EP. 3: Acalabrutinib as Frontline Therapy for CLL

ByWilliam G. Wierda, MD, PhD,Catherine C. Coombs, MD

January 31st 2022

Features that distinguish acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, from ibrutinib as frontline therapy for patients with chronic lymphocytic leukemia.

EP. 4: Implications for Zanubrutinib as CLL Treatment

ByWilliam G. Wierda, MD, PhD,Deborah M. Stephens, DO

January 31st 2022

An overview of safety and efficacy data for a third-generation Bruton tyrosine kinase inhibitor, zanubrutinib, as treatment for patients with chronic lymphocytic leukemia.

EP. 5: Frontline Therapy for CLL: Treatment Selection Based on Patient and Treatment Factors

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

February 7th 2022

Variables that impact which Bruton tyrosine kinase inhibitor is most appropriate as frontline therapy for patients with newly diagnosed chronic lymphocytic leukemia and the role of patient and disease factors in treatment selection.

EP. 6: Fixed-Duration Therapy in Frontline CLL: Ibrutinib Plus Venetoclax

ByWilliam G. Wierda, MD, PhD,Anthony R. Mato, MD, MSCE,Catherine C. Coombs, MD

February 7th 2022

Key takeaways from the CAPTIVATE and GLOW trials of ibrutinib plus venetoclax as fixed-duration frontline therapy for chronic lymphocytic leukemia.

EP. 7: Fixed-Duration Therapy in Frontline CLL: Venetoclax Plus Obinutuzumab

ByWilliam G. Wierda, MD, PhD,Anthony R. Mato, MD, MSCE,Catherine C. Coombs, MD,Deborah M. Stephens, DO

February 14th 2022

The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.

EP. 8: Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE

February 14th 2022

Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.

EP. 9: Chemotherapy-Free Regimens as Frontline Therapy in CLL

ByWilliam G. Wierda, MD, PhD,Nicole Lamanna, MD,Catherine C. Coombs, MD,Anthony R. Mato, MD, MSCE,Jacqueline Barrientos, MD, MS

February 21st 2022

Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.

EP. 10: Treating CLL With Anti-CD20 Antibody Regimens

ByWilliam G. Wierda, MD, PhD,Deborah M. Stephens, DO,Catherine C. Coombs, MD,Nicole Lamanna, MD

February 21st 2022

Recommendations for combining an anti-CD20 antibody with a Bruton tyrosine kinase inhibitor or venetoclax in doublet or triplet regimens for the treatment for chronic lymphocytic leukemia (CLL).

EP. 11: Novel Therapies for CLL: Sequencing Strategies

ByWilliam G. Wierda, MD, PhD,Anthony R. Mato, MD, MSCE,Nicole Lamanna, MD,Catherine C. Coombs, MD

February 28th 2022

Factors that impact decisions for frontline and subsequent lines of therapy for patients with chronic lymphocytic leukemia.

EP. 12: Novel Therapies for CLL in the Context of COVID-19

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS

February 28th 2022

What to know in terms of COVID-19 vaccine responses in patients with chronic lymphocytic leukemia on novel targeted therapies.

EP. 13: Noncovalent BTK Inhibitors in CLL

ByWilliam G. Wierda, MD, PhD,Jacqueline C. Barrientos, MD,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD,Deborah M. Stephens, DO

March 7th 2022

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

EP. 14: PI3K Inhibitors for CLL

ByWilliam G. Wierda, MD, PhD,Jacqueline Barrientos, MD, MS,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

March 7th 2022

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

EP. 15: CAR T-Cell Therapies in CLL

ByWilliam G. Wierda, MD, PhD,Jacqueline C. Barrientos, MD, MS,Catherine C. Coombs, MD,Nicole Lamanna, MD,Anthony R. Mato, MD, MSCE,Deborah M. Stephens, DO

March 14th 2022

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

EP. 16: Optimizing the Treatment of CLL With Novel Therapies